neurocare group
neurocare group AG is a German-based medical technology company that delivers personalized mental health treatment via a proprietary Digital Therapy Platform combining neuromodulation hardware (TMS, neurofeedback, tDCS) with AI-enabled brain mapping and sleep analysis, serving patients and clinics across Germany, Netherlands, UK/Ireland, US, Australia, and MENA.
- Company typePrivate
- Founded2015
- HeadquartersMunich, Germany
- Headcount51–100
- GTM typeB2B and B2C
- OfferingServices
What neurocare group does
neurocare group AG is a Munich/Ilmenau-based private medical technology company founded in 2015 that operates a vertically integrated platform for personalized mental health treatment. The company combines proprietary hardware (including the FDA-cleared Apollo TMS Therapy System, TMS neuronavigation, neurofeedback systems, EEG/QEEG devices, and tDCS/tES stimulators) with its Digital Therapy Platform, which integrates brain mapping, sleep analysis, and AI to support personalized therapy protocols across its own and partner clinics. The platform targets treatment-resistant depression, OCD, ADHD, insomnia, and anxiety through non-invasive neuromodulation.
The company monetizes through five revenue streams: hardware sales (TMS devices and accessories to clinics globally), managed clinic services (20+ owned clinics across Germany, Netherlands, UK/Ireland, US, and Australia), professional training through the neurocare Academy (online and in-person courses), software platform licensing (Digital Therapy Platform to third-party clinics), and market-entry sales enabled by regional regulatory approvals (notably Saudi Arabia following May 2026 SFDA approval). Sub-brands include Apollo TMS, neurocare Academy, QEEG Labs, and acquired entities MAG & More, Smart TMS, MeJa Psychologie, and neuroConn devices.
Strategic activity in 2024-2026 has accelerated: EUR 35.3 million raised across rounds led by TVM Capital Healthcare with Impact Expansion; acquisitions of Smart TMS (UK/Ireland, 9 clinics) and MeJa Psychologie (Netherlands, expanding to 11 clinics); multiple FDA clearances (adolescent depression, OCD, iTBS protocol); Japan patent grant and Kyowa joint venture; MDMA approval in Saudi Arabia; and 2026 partnerships with NRx Pharmaceuticals, Zeta Surgical, and Emobot Health extending into integrated drug-device therapy, robotic TMS, and AI depression monitoring. The company maintains ISO 9001 certification for Netherlands clinic operations and holds a planned public listing as a stated objective.
neurocare group firmographics
Firmographics- Name
- neurocare group
- Legal name
- neurocare group AG
- Website
- https://neurocaregroup.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- neurocare group AG is a German-based medical technology company that delivers personalized mental health treatment via a proprietary Digital Therapy Platform combining neuromodulation hardware (TMS, neurofeedback, tDCS) with AI-enabled brain mapping and sleep analysis, serving patients and clinics across Germany, Netherlands, UK/Ireland, US, Australia, and MENA.
- Ownership category
- akta.pro rank
neurocare group industry classification
Industry- Product category
- Neuromodulation & Mental Health Technology
- NAICS
- Outpatient Mental Health and Substance Abuse Centers (621420), Offices of Physicians, Mental Health Specialists (621112), Offices of Mental Health Practitioners (except Physicians) (621330)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Services-Health Services (8000), Services-Offices & Clinics Of Doctors Of Medicine (8011)
- akta.pro primary industry
- Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI)
- akta.pro secondary industries
- Neurology Telemedicine Platforms (HLALAGAC), General Mental Health Therapy Platforms (Talk Therapy) (HLALAEAA)
Keywords
Where neurocare group is headquartered
LocationHeadquarters
- HQ city
- Munich
- HQ country
- Germany
- HQ region
- Europe
Offices16 records
Markets served
neurocare group business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- Hardware Sales (TMS Devices): Sale of medical devices including Apollo TMS systems, TMS neuronavigation, tDCS/tES devices, neurofeedback systems, and EEG/QEEG equipment to clinics and healthcare providers globally.
- Clinic Services: Operation of owned clinics providing neuromodulation therapies (TMS, neurofeedback, tDCS) and psychotherapy to patients with mental health conditions. Revenue from treatment sessions across owned clinic network in Germany, Netherlands, Australia, US, UK, and Ireland.
- Training & Academy Services: Professional education and training services for healthcare professionals including TMS courses, neurofeedback workshops, and tDCS training through online LMS platform and in-person workshops worldwide.
- Software Platform Licensing: Licensing of Digital Therapy Platform to third-party clinics for personalized treatment management and quality assurance in mental health delivery.
- International Expansion & Market Entry: MDMA approval obtained for TMS device sales in Saudi Arabia, enabling market entry into MENA region. Strategic expansion through partnerships and regulatory approvals in new geographic markets.
Go-to-market motion2 records
Distribution channels5 records
Marketing channels8 records
neurocare group product offering
Product offeringCore offering
neurocare group provides personalized mental health care through an integrated best-practice platform combining proprietary AI-powered Digital Therapy Platform with FDA-cleared neuromodulation hardware (TMS, tDCS/tES, neurofeedback, EEG/QEEG) and a global network of operated and partner clinics. The company sells TMS therapy systems and software platform licenses to third-party clinics and hospitals while also delivering treatment services directly to patients through its own clinics across Germany, the US, Australia, the Netherlands, the UK, and Ireland.
Product overview
neurocare group offers a unified best practice platform for personalized mental health care, combining proprietary hardware devices, software, and clinical services. The core offering includes the Digital Therapy Platform (DTP), which integrates AI, brain mapping, and sleep analysis for personalized treatment. The hardware portfolio spans TMS Systems (Apollo TMS Therapy), TMS Neuronavigation, tES & tDCS Devices, Neurofeedback Systems, EEG & QEEG Systems, and Actigraphy Devices. The company operates a global network of clinics (Germany, US, Australia, Netherlands, UK, Ireland) and offers professional training through neurocare Academy. The platform is supported by acquired brands including MAG & More and neuroConn devices, with recent expansion through Smart TMS Clinics acquisition.
Differentiator
Problem solved
Functional benefit
Brands
- Apollo TMS: TMS therapy devices that have received FDA clearance for depression, OCD, and adolescent major depression treatment
- Digital Therapy Platform (DTP)
- neurocare Academy
- QEEG Labs
- Neuronavigation
Products and services
- Digital Therapy Platform (DTP) Integrated software platform that empowers clinicians to embed leading therapy innovations, combining AI, brain mapping, and sleep analysis to support personalized mental health treatment. Deployed in neurocare's own and third-party clinics worldwide.
- Apollo TMS Therapy System FDA-cleared Transcranial Magnetic Stimulation (TMS) device for treatment of depression, OCD, and adolescent major depressive disorder. Features industry-leading iTBS (intermittent Theta Burst Stimulation) protocol.
- TMS Systems Systems for Transcranial Magnetic Stimulation applied in clinical and research settings, including Apollo TMS device and accessories for treating mental health conditions.
- TMS Neuronavigation Systems Leading neuronavigation systems for advanced practice and research of Transcranial Magnetic Stimulation, enabling precise targeting during TMS procedures.
- tES & tDCS Devices Stimulators for clinical practice and research in tDCS (transcranial Direct Current Stimulation), tACS (transcranial Alternating Current Stimulation), and tRNS (transcranial Random Noise Stimulation), compatible with advanced EEG and neuroimaging.
- Neurofeedback Systems Neurofeedback systems with optional biofeedback extensions and precision artefact control, used for conditions including ADHD, insomnia, and other neurological conditions.
- EEG & QEEG Systems Electroencephalogram (EEG) technology, purpose-built and compatible with neuromodulation modalities for practice and research, including brain mapping and quantitative EEG analysis capabilities.
- Actigraphy Devices Sleep hygiene assessment devices for patient care and research, used to monitor sleep patterns and support personalized treatment planning.
- neurocare Academy Professional training platform offering online and hands-on courses in TMS, neurofeedback, and tDCS for healthcare professionals worldwide.
- neurocare Clinics Global network of best practice clinics providing personalized mental health treatments using TMS, neurofeedback, tDCS, and psychotherapy across Germany, US, Australia, Netherlands, UK, and Ireland.
Quantifiable outcome
- 90% response rate and 70% remission rate in ONE-D Trial for accelerated TMS protocol (preliminary study)
- +2 more outcomes
Companies that use neurocare group
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
neurocare group technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
neurocare group partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core, strategic and minor.
- NRx PharmaceuticalscoreJoint offering launching nationwide program integrating TMS, medications, and psychotherapy to treat Depression, PTSD, and other mental health conditions. Combines neurocare's TMS technology with NRx's pharmaceutical pipeline.
- Zeta SurgicalstrategicStrategic partnership for robotic-enabled TMS technology development and integration.
- Smart TMScoreAcquired Smart TMS clinics (UK's largest TMS provider with 9 clinics) enabling expansion into UK and Ireland markets and integration of Digital Therapy Platform into UK clinics. Rebranded to neurocare in April 2025.
- MeJa PsychologiecorePerinatal mental health specialists acquired to expand neurocare's Netherlands clinic network to 11 locations and mark key step into pregnancy/postpartum mental health care.
- Stimit AGminorStrategic cooperation with Stimit AG, a company developing solutions for neuromodulation and neuroplasticity enhancement.
- MAG & MorecoreGerman-based leader of Transcranial Magnetic Stimulation devices joined forces with neurocare group, combining MAG & More's TMS expertise with neurocare's platform approach.
- Fondazione Policlinico GemellistrategicStrategic cooperation in Rome to deliver neuromodulation treatments, expanding neurocare's European footprint.
- KyowastrategicEquity participation agreement paving the way for strategic joint venture in Japan, supporting neurocare's Japan market entry following patent grant.
- Mid-Ohio Behavioral HealthstrategicCollaborative arrangement expanding neurocare US footprint through partnership with Midwest behavioral health provider.
Scale indicators10 records
Recent moves11 records
Expansion highlights7 records
neurocare group competitors and assessment
Company assessmentBroad incumbents
- Pear Therapeutics: Digital therapeutics company developing prescription software-based treatments for mental health conditions including depression. Overlaps with neurocare's Digital Therapy Platform approach to mental health delivery.
- Saluda Medical: Medical device company developing neuromodulation technologies for chronic pain and other conditions. Broader incumbent in the neuromodulation space with overlap in neurostimulation expertise.
Direct peers
- Brainsway: Israel-based medical device company that develops and markets Deep TMS systems for treatment of depression, OCD, and other neurological disorders. Direct competitor in TMS technology with FDA-cleared systems.
- Neuronetics: Commercial-stage medical technology company focused on designing, developing, and marketing TMS products (NeuroStar) for psychiatric and neurological disorders. Most direct competitor to neurocare's Apollo TMS in the treatment-resistant depression market.
- Sooma: Finland-based medical device company developing tDCS (transcranial Direct Current Stimulation) devices for depression and other neurological conditions. Direct competitor in the tDCS modality that neurocare offers.
- Flow Neuroscience: Sweden-based company offering a direct-to-consumer TMS device for depression treatment combined with behavioral therapy. Competes with neurocare in the personalized mental health neuromodulation space.
- Magstim: UK-based manufacturer of TMS stimulators and coils used in research, clinical, and neurosurgical applications. Competes with neurocare in the TMS hardware market globally.
- Greenbrook TMS: US-based operator of TMS treatment centers for major depressive disorder and other mental health conditions. Direct competitor to neurocare's clinic services business model in North America.
Emerging players
- eNeura: Developer of non-invasive neuromodulation devices (single-pulse TMS) for migraine treatment. Adjacent to neurocare in the non-invasive neuromodulation device category.
- Mindstrong Health: Digital mental health platform using AI and biomarkers to monitor and treat mental health conditions. Overlaps with neurocare's AI-enabled Digital Therapy Platform approach to mental health personalization.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
neurocare group social profiles
Digital presenceneurocare group compliance and trust
Trust signalCompliance4 records
neurocare group financial estimates
Financial estimateRevenue estimate
Valuation estimate
neurocare group leadership team
Management profileNumber of profiles
Profiles21 records
neurocare group subsidiaries and ownership
Company hierarchySubsidiaries4 records
neurocare group funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
neurocare group M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about neurocare group
What does neurocare group do?
neurocare group provides personalized mental health care through an integrated best-practice platform combining proprietary AI-powered Digital Therapy Platform with FDA-cleared neuromodulation hardware (TMS, tDCS/tES, neurofeedback, EEG/QEEG) and a global network of operated and partner clinics. The company sells TMS therapy systems and software platform licenses to third-party clinics and hospitals while also delivering treatment services directly to patients through its own clinics across Germany, the US, Australia, the Netherlands, the UK, and Ireland.
Is neurocare group a public or private company?
neurocare group is a private company. It is classified as venture growth investor backed and is currently operating.
When was neurocare group founded?
neurocare group was founded in 2015. It employs 51 to 100 people.
Where is neurocare group based?
neurocare group is headquartered in Munich, Germany, in the Europe region.
How does neurocare group make money?
Five revenue lines are on record. Hardware Sales (TMS Devices) is the primary driver. The others are clinic Services, training & Academy Services, software Platform Licensing and international Expansion & Market Entry.
Who are neurocare group's main competitors?
Broad incumbents on record are Pear Therapeutics and Saluda Medical. Direct peers are Brainsway, Neuronetics, Sooma, Flow Neuroscience, Magstim and Greenbrook TMS. Emerging players are eNeura and Mindstrong Health.
Does neurocare group have an API?
No public API is recorded for neurocare group.
What industry is neurocare group in?
neurocare group's product category is Neuromodulation & Mental Health Technology. Its primary akta.pro industry code is HLACANAI, Behavioral Health & Neurocognitive Therapeutics (Digital), with a secondary code of HLALAGAC, Neurology Telemedicine Platforms. Its NAICS code is 621420 and its SIC code is 3845.